肝硬化难治性腹水的诊治与血管收缩药物的应用

doi:10.3969/j.issn.1672-5069.2015.05.004

Abstract

Xiao Li，Yang Ling. Application of vasoconstrictors in management of patients with refractory ascites[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2015, 18(5): 460-462.

[1] D'Amico G，Garcia-Tsao G，Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: A systematic review of 118 studies. J Hepatol，2006，44（1）:217-231.
[2] Planas R. Natural history of patients hospitalized for management of cirrhotic ascites. Clin Gastroenterol Hepatol，2006，4（11）:1385-1394.
[3] Ochs A. The transjugular intrahepatic portosystemic stent-shunt procedure for refractory ascites. N Engl J Med，1995，332（18）:1192-1197.
[4] Runyon BA. Management of adult patients with ascites due to cirrhosis:an update. Hepatology，2009，49（6）:2087-2107.
[5] EASL clinical practice guidelines on the management of ascites，spontaneous bacterial peritonitis，and hepatorenal syndrome in cirrhosis. J Hepatol，2010，53（3）:397-417.
[6] Moore KP. Guidelines on the management of ascites in cirrhosis. Gut，2006，55（suppl_6）:vi1-vi12.
[7] Gines P. Management of cirrhosis and ascites. N Engl J Med， 2004，350（16）:1646-1654.
[8] Singhal S. Management of refractory ascites. Am J Ther，2012， 19（2）:121-132.
[9] Moore KP. The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club. Hepatology，2003，38（1）:258-266.
[10] Lenz K. Treatment and management of ascites and hepatorenal syndrome:an update. Therap Adv Gastroenterol，2015，8（2）:83-100.
[11] Singh V. Midodrine and clonidine in patients with cirrhosis and refractory or recurrent ascites:a randomized pilot study. Am J Gastroenterol，2013，108（4）:560-567.
[12] Singh V. Midodrine in patients with cirrhosis and refractory or recurrent ascites:a randomized pilot study. J Hepatol，2012，56（2）:348-354.
[13] Sola-Vera J. Randomized trial comparing albumin and saline in the prevention of paracentesis-induced circulatory dysfunction in cirrhotic patients with ascites. Hepatology，2003，37（5）:1147-1153.
[14] Singh V. Midodrine versus albumin in the prevention of paracentesis-induced circulatory dysfunction in cirrhotics:a randomized pilot study. Am J Gastroenterol，2008，103（6）:1399-1405.
[15] Kalambokis G. Effects of a 7-day treatment with midodrine in non-azotemic cirrhotic patients with and without ascites. J Hepatol， 2007，46（2）: 213-221.
[16] Hamdy H. Comparison of midodrine and albumin in the prevention of paracentesis-induced circulatory dysfunction in cirrhotic patients:a randomized pilot study. J Clin Gastroenterol，2014，48（2）:184-188.
[17] Singh V. Midodrine in patients with cirrhosis and refractory or recurrent ascites:a randomized pilot study. J Hepatol，2012，56（2）:348-354.
[18] Fimiani B. The use of terlipressin in cirrhotic patients with refractory ascites and normal renal function:A multicentric study. Eur J Intern Med，2011，22（6）:587-590.
[19] Singh V. Terlipressin versus albumin in paracentesis-induced circulatory dysfunction in cirrhosis:a randomized study. J Gastroenterol Hepatol，2006，21（1 Pt 2）:303-307.
[20] Lenaerts A. Comparative pilot study of repeated large volume paracentesis vs the combination on clonidine-spironolactone in the treatment of cirrhosis-associated refractory ascites. Gastroenterol Clin Biol，2005，29（11）:1137-1142.
[21] Schrier RW. Tolvaptan，a selective oral vasopressin V2-receptor antagonist，for hyponatremia. N Engl J Med，2006，355（20）: 2099-2112.
[22] Cardenas A. Tolvaptan， an oral vasopressin antagonist，in the treatment of hyponatremia in cirrhosis. J Hepatol，2012，56（3）: 571-578.
[23] Okita K. A multicenter，open-label，dose-ranging study to exploratively evaluate the efficacy，safety，and dose-response of tolvaptan in patients with decompensated liver cirrhosis. J Gastroenterol，2010，45（9）:979-987.
[24] Wong F. Satavaptan for the management of ascites in cirrhosis: efficacy and safety across the spectrum of ascites severity. Gut，2012，61（1）:108-116.
[25] Bureau C.Serum bilirubin and platelet count:a simple predictive model for survival in patients with refractory ascites treated by TIPS. J Hepatol，2011，54（5）:901-907.
[26] Gaba RC.Survival benefit of TIPS versus serial paracentesis in patients with refractory ascites:a single institution case-control propensity score analysis. Clin Radiol，2015，70（5）: e51-7.

Application of vasoconstrictors in management of patients with refractory ascites

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Zhuang Ying, Lin Zhihui.. Clinical manifestations and diagnosis of portal vein thrombosis [J]. Journal of Practical Hepatology, 2019, 22(6): 765-767.
[2]	Yang Caiyong, Chen Na, Li Kui, et al.. Clinical significance of peripheral blood Treg and Th17 cells in patients with chronic hepatitis C and hepatitis C-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(6): 868-871.
[3]	Zhu Yage, Liu Jinfeng.. Therapeutic efficacy of adenosine methionine and glycyrrhizin combination in treatment of patients with alcoholic cirrhosis and its effect on serum BGP levels [J]. Journal of Practical Hepatology, 2019, 22(6): 872-875.
[4]	Wu Dan Ma Xiangying.. Insulin resistance,carotid atherosclerosis and left ventricular function in patients with NAFLD-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(6): 876-879.
[5]	Chen Meimei, Duan Xiaoyan, Cao Haixia, et al.. Improvement of clinical symptoms and serum hepatic fibrosis markers in patients with primary biliary cirrhosis by compound Biejiaruangan tablets [J]. Journal of Practical Hepatology, 2019, 22(6): 880-883.
[6]	Liu Li, Yang Lie, Chen Haiyang, et al.. Changes of hemodynamics after splenectomy combined with pericardial devascularization in patients with cirrhotic portal hypertention complicated by splenic artery steal syndrome [J]. Journal of Practical Hepatology, 2019, 22(6): 884-887.
[7]	He Zhi’an, Yu Liping, Lai Jiangqiong, et al.. Evaluation of varices bleeding and portal vein thrombosis by ARFI in patients with cirrhosis and esophagogastric varices [J]. Journal of Practical Hepatology, 2019, 22(6): 888-891.
[8]	Wang Yueyuan, Wang Yan, Zhang Dandan. Short-term efficacy of terlipressin and octreotide combination in treatment of cirrhotic patients complicated by hepatorenal syndrome [J]. Journal of Practical Hepatology, 2019, 22(5): 684-687.
[9]	Zhang Mei, Shi Xiuying, Li Linjuan, et al. Hepatic expression of interferon inducible protein -10 in patients with hepatitis B liver cirrhosis and hepatogenic diabetes mellitus [J]. Journal of Practical Hepatology, 2019, 22(5): 688-691.
[10]	Dan Zhuyongji, Liu Zhilan, Lu Yanyan, et al. Efficacy of endoscopic sequential variceal 1igation plus sclerotherapy in treatment of patients with hepatitis B-induced liver cirrhosis complicated by esophageal gastric varices bleeding [J]. Journal of Practical Hepatology, 2019, 22(5): 692-695.
[11]	Huang Hanjun, Lu Fengrong, Zhang Can. Clinical value of MRI scanning based on exchange hemodynamics model in evaluating liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(5): 696-699.
[12]	Zhao Fangfang, Zhai Yongzhen, Feng Guohe. Efficacy and safety of autologous peripheral blood stem cell transplantation in patients with hepatitis B cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(5): 700-703.
[13]	Chen Shan, Zhuang Huashuai, Xing Yixi, et al. Preventive application of meropenem in patients with liver cirrhosis complicated by upper gastrointestinal bleeding [J]. Journal of Practical Hepatology, 2019, 22(5): 704-707.
[14]	Xu Qilin, Hao Shaohuan, Ran Bo. Risk factors of portal vein thrombosis after splenectomy in patients with liver cirrhosis and portal hypertension [J]. Journal of Practical Hepatology, 2019, 22(5): 708-711.
[15]	Jin Lianghong, Li Xingjie, Guan Hongbo, et al. Clinical value of dual-energy CT iodine quantification combined with dynamic contrast-enhanced MRI in evaluating hepatic hemodynamics and liver functions in patients with hepatitis B liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(5): 712-715.